Donate
Suivez-nous sur Linked In
Suivez-nous sur Youtube
See all news & events

Where oncology and autoimmunity
converge to accelerate
immunotherapies. CAR-T, bispecific
antibodies, immune checkpoint
inhibitors drive innovations for patients.

One ambitious objective: to cure cancer
and autoimmune diseases

FHU CARE² explores the deep connections between
autoimmunity and cancer to develop
curative immunotherapies.

Our Research Targets

INNOVATE

Developing
next-generation
tools for experimental
and clinical
immunotherapies

Understand

Decoding common
and opposite immune
regulation mechanisms
in cancer and
autoimmune diseases

Treat

Clinical trials
to test CAR-T
and bispecific
antibody strategies

Teach

Advancing education
and training in
immunotherapies

Now, CAR-T and bispecific
therapies offer unprecedented
hope-with patients achieving
lasting remission beyond two years.
FHU CARE² is pioneering this new
frontier toward curative
immunotherapies.

Prof. Xavier Mariette

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

Dr. Samuel Bitoun

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

See on

Dr. Camille Bigenwald

“With FHU CARE²,
we harness the power
of CAR T and bispecific
therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and hemato-oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications

A genetic variant of BAFF is associated with the risk of lymphoma in Sjögren disease.

Beydon M, Dulin M, Ly B, Verstuyft C, Cardoso A, Juge PA, Dieudé P, Lessard CJ, Khatri B, Radziszewski M, Le Guern V, Gottenberg JE, Seror R, Mariette X, Nocturne G.

Ann Rheum Dis. | 2026 Jan 14. doi: 10.1016/j.ard.2025.12.010. PMID: 41539891.

Salivary gland organoids and the future of modeling autoimmune epithelitis in Sjögren's disease.

Yang T, Goudarzi N, Kroese FGM, Mariette X, Pringle S, Nocturne G.

Curr Opin Immunol. | 2026 Feb;98:102707. doi: 10.1016/j.coi.2025.102707. Epub 2025 Dec 11. PMID: 41385979 Review.

See all publications